Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

NCT03756298 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

284

Enrollment

OTHER_GOV

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Atezolizumab
DRUG: Capecitabine

Sponsor

National Cancer Center, Korea